Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants

Cybin Inc. (NEO:CYBN) (OTCMKTS: CLXPF), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, reports that its Company-sponsored feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow, is actively recruiting participants. The study is evaluating the participants experience wearing Kernel Flow while in an altered state of consciousness following the administration of ketamine.

Participants will receive either a low dose of ketamine or placebo while wearing the Kernel Flow headset, which is equipped with hi-tech sensors to record brain activity and will report their experience using structured questionnaires and validated assessments during study visits and a follow-up. The study will also evaluate brain activity before and after the administration of the study agents – low-dosed ketamine or placebo.

The feasibility study using Kernel Flow offers an opportunity for researchers and our study participants to quantifiably gather information on a psychedelic experience. Until now, our understanding of the psychedelic experience has been fairly subjective. This study may lead to larger studies that have the potential to bridge the gap between bringing psychedelics to therapeutics as we learn more about the advantages of these important molecules on brain activity and overall mental wellbeing.

Doug Drysdale, Cybin’s Chief Executive Officer

To learn more about the study eligibility criteria, please visit kernel.com/participate.

About Kernel Flow

Kernel Flow is a wearable headset that measures brain activity by recording local changes in blood oxygenation. It is adjustable, can accommodate nearly anyone and is safe. Kernel Flow is groundbreaking neurotechnology because it reduces loud, expensive, and room-sized equipment to a head-worn apparatus while providing neural activity data of the highest possible optical quality. This combination has never existed in such a commercial and scalable device, all factors for why brain interfaces and neuroimaging technology has largely remained in academic labs or hospital basements and why mental health diagnosis and treatment have behavioral, instead of biomarker, endpoints. The entire system is the size and look of a bicycle helmet and could, in the future, be more broadly used for neuroscientific or physiological studies of brain activity during psychedelic use.

To read the rest of the Press Release in its entirety, click here.

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More